ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 95 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.79 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $890,000 | -21.2% | 148,506 | -2.9% | 0.01% | -31.2% |
| Q4 2018 | $1,130,000 | -62.2% | 152,954 | -25.7% | 0.02% | -57.9% |
| Q3 2018 | $2,988,000 | -38.2% | 205,751 | -15.1% | 0.04% | -43.3% |
| Q2 2018 | $4,838,000 | +266.8% | 242,251 | +221.9% | 0.07% | +235.0% |
| Q1 2018 | $1,319,000 | -39.6% | 75,265 | -15.1% | 0.02% | -37.5% |
| Q4 2017 | $2,185,000 | -12.1% | 88,600 | -8.0% | 0.03% | -8.6% |
| Q3 2017 | $2,486,000 | -5.1% | 96,300 | -0.3% | 0.04% | -12.5% |
| Q2 2017 | $2,620,000 | +7.8% | 96,600 | +18.5% | 0.04% | -2.4% |
| Q1 2017 | $2,430,000 | – | 81,500 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |